In vivo applications of single chain Fv (variable domain) (scFv) fragments

Antibodies

Volumn 2, Issue 2, 2013, Pages 193-208

  Monnier, Philippe P ^a,b   Vigouroux, Robin J ^a,b   Tassew, Nardos G ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adeno associated virus (AAV); Immunotherapy; In vivo expression; Recombinant antibodies; ScFv

Indexed keywords

AMYLOID BETA PROTEIN; CD7 ANTIGEN; CHEMOKINE RECEPTOR CCR4; GLUCOSE REGULATED PROTEIN 78; INSULIN RECEPTOR; RECOMBINANT IMMUNOTOXIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TENASCIN; TRANSCRIPTION FACTOR PAX6; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANGIOGENESIS; BLOOD BRAIN BARRIER; CANCER THERAPY; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DRUG MEGADOSE; GENETIC MANIPULATION; HUMAN; HUNTINGTON CHOREA; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFECTION RATE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN DOMAIN; RADIOACTIVITY; REVIEW; VIRAL GENE DELIVERY SYSTEM;

EID: 84907983837     PISSN: 20734468     EISSN: None     Source Type: Journal    
DOI: 10.3390/antib2020193     Document Type: Review

References (84)

1. Ward, E. S.; Martinez, C.; Vaccaro, C.; Zhou, J.; Tang, Q.; Ober, R. J. From sorting endosomes to exocytosis: Association of Rab4 and Rab11 GTPases with the Fc receptor, FcRn, During recycling. Mol. Biol. Cell 2005, 16, 2028-2038.
2. Woof, J. M.; Burton, D. R. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat. Rev. Immunol. 2004, 4, 89-99.
3. Adams, G. P.; Weiner, L. M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 2005, 23, 1147-1157.
4. Wu, A. M.; Senter, P. D. Arming antibodies: Prospects and challenges for immunoconjugates. Nat. Biotechnol. 2005, 23, 1137-1146.
5. Holliger, P.; Hudson, P. J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 2005, 23, 1126-1136.
6. Porter, R. R. The hydrolysis of rabbit y-globulin and antibodies with crystalline papain. Biochem. J. 1959, 73, 119-126.
7. Hudson, P. J. Recombinant antibody fragments. Curr. Opin. Biotechnol. 1998, 9, 395-402.
8. Little, M.; Kipriyanov, S. M.; le Gall, F.; Moldenhauer, G. Of mice and men: Hybridoma and recombinant antibodies. Immunol. Today 2000, 21, 364-370.
9. Skerra, A.; Pluckthun, A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 1988, 240, 1038-1041.
10. Hust, M.; Jostock, T.; Menzel, C.; Voedisch, B.; Mohr, A.; Brenneis, M.; Kirsch, M. I.; Meier, D.; Dubel, S. Single chain Fab (scFab) fragment. BMC Biotechnol. 2007, 7, 14.
11. Edwardraja, S.; Sriram, S.; Govindan, R.; Budisa, N.; Lee, S. G. Enhancing the thermal stability of a single-chain Fv fragment by in vivo global fluorination of the proline residues. Mol. Biosyst. 2011, 7, 258-265.
12. Nelson, A. L. Antibody fragments: Hope and hype. MAbs 2010, 2, 77-83.
13. Nelson, A. L.; Reichert, J. M. Development trends for therapeutic antibody fragments. Nat. Biotechnol. 2009, 27, 331-337.
14. Maynard, J.; Georgiou, G. Antibody engineering. Annu. Rev. Biomed. Eng. 2000, 2, 339-376.
15. Bird, R. E.; Hardman, K. D.; Jacobson, J. W.; Johnson, S.; Kaufman, B. M.; Lee, S. M.; Lee, T.; Pope, S. H.; Riordan, G. S.; Whitlow, M. Single-chain antigen-binding proteins. Science 1988, 242, 423-426.
16. Huston, J. S.; Levinson, D.; Mudgett-Hunter, M.; Tai, M. S.; Novotny, J.; Margolies, M. N.; Ridge, R. J.; Bruccoleri, R. E.; Haber, E.; Crea, R.; et al. Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA 1988, 85, 5879-5883.
17. Ahmad, Z. A.; Yeap, S. K.; Ali, A. M.; Ho, W. Y.; Alitheen, N. B.; Hamid, M. scFv antibody: Principles and clinical application. Dev. Immunol. 2012, 2012, 980250.
18. Whitlow, M.; Bell, B. A.; Feng, S. L.; Filpula, D.; Hardman, K. D.; Hubert, S. L.; Rollence, M. L.; Wood, J. F.; Schott, M. E.; Milenic, D. E.; et al. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng. 1993, 6, 989-995.
19. Alfthan, K.; Takkinen, K.; Sizmann, D.; Soderlund, H.; Teeri, T. T. Properties of a single-chain antibody containing different linker peptides. Protein Eng. 1995, 8, 725-731.
20. Baneyx, F. Recombinant protein expression in Escherichia coli. Curr. Opin. Biotechnol. 1999, 10, 411-421.
21. Ho, M.; Nagata, S.; Pastan, I. Isolation of anti-CD22 Fv with high affinity by Fv display on human cells. Proc. Natl. Acad. Sci. USA 2006, 103, 9637-9642.
22. Galeffi, P.; Lombardi, A.; Pietraforte, I.; Novelli, F.; Di Donato, M.; Sperandei, M.; Tornambe, A.; Fraioli, R.; Martayan, A.; Natali, P. G.; et al. Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems. J. Transl. Med. 2006, 4, 39.
23. Choo, A. B.; Dunn, R. D.; Broady, K. W.; Raison, R. L. Soluble expression of a functional recombinant cytolytic immunotoxin in insect cells. Protein Expres. Purif. 2002, 24, 338-347.
24. Chowdhury, P. S.; Viner, J. L.; Beers, R.; Pastan, I. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc. National. Acad. Sci. USA 1998, 95, 669-674.
25. Deckert, P. M. Current constructs and targets in clinical development for antibody-based cancer therapy. Curr. Drug Targets 2009, 10, 158-175.
26. Cheng, K. T. Radioiodinated-anti-TAG-72 covalently linked CC49 divalent single-chain Fv antibody. In Molecular Imaging and Contrast Agent Database (MICAD); National Center for Biotechnology Information: Bethesda, MD, USA, 2004.
27. Kobayashi, N.; Odaka, K.; Uehara, T.; Imanaka-Yoshida, K.; Kato, Y.; Oyama, H.; Tadokoro, H.; Akizawa, H.; Tanada, S.; Hiroe, M.; et al. Toward in vivo imaging of heart disease using a radiolabeled single-chain Fv fragment targeting tenascin-C. Anal. Chem. 2011, 83, 9123-9130.
28. Robinson, M. K.; Doss, M.; Shaller, C.; Narayanan, D.; Marks, J. D.; Adler, L. P.; Gonzalez Trotter, D. E.; Adams, G. P. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res. 2005, 65, 1471-1478.
29. Sundaresan, G.; Yazaki, P. J.; Shively, J. E.; Finn, R. D.; Larson, S. M.; Raubitschek, A. A.; Williams, L. E.; Chatziioannou, A. F.; Gambhir, S. S.; Wu, A. M. 124I-labeled engineered anti-CEAcea minibodies and diabodies allow high-contrast, antigen-specific small-animal PETimaging of xenografts in athymic mice. J. Nucl. Med. 2003, 44, 1962-1969.
30. Chari, R. V. Targeted delivery of chemotherapeutics: Tumor-activated prodrug therapy. Adv. Drug Deliv. Rev. 1998, 31, 89-104.
31. Gattenlohner, S.; Jorissen, H.; Huhn, M.; Vincent, A.; Beeson, D.; Tzartos, S.; Mamalaki, A.; Etschmann, B.; Muller-Hermelink, H. K.; Koscielniak, E.; et al. A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model. J. Biomed. Biotechnol. 2010, 2010, 187621.
32. Tong, Q.; Liu, K.; Lu, X. M.; Shu, X. G.; Wang, G. B. Construction and characterization of a novel fusion protein MG7-scFv/SEB against gastric cancer. J. Biomed. Biotechnol. 2010, 2010, 121094.
33. Tassew, N. G.; Charish, J.; Chestopalova, L.; Monnier, P. P. Sustained in vivo inhibition of protein domains using single-chain Fv recombinant antibodies and its application to dissect rgma activity on axonal outgrowth. J. Neurosci. 2009, 29, 1126-1131.
34. Di Lullo, E.; Haton, C.; Le Poupon, C.; Volovitch, M.; Joliot, A.; Thomas, J. L.; Prochiantz, A. Paracrine Pax6 activity regulates oligodendrocyte precursor cell migration in the chick embryonic neural tube. Development 2011, 138, 4991-5001.
35. Curigliano, G.; Spitaleri, G.; Dettori, M.; Locatelli, M.; Scarano, E.; Goldhirsch, A. Vaccine immunotherapy in breast cancer treatment: Promising, but still early. Expert Rev. Anticancer Ther. 2007, 7, 1225-1241.
36. Bard, F.; Cannon, C.; Barbour, R.; Burke, R. L.; Games, D.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000, 6, 916-919.
37. Sidhu, S. S.; Fellouse, F. A. Synthetic therapeutic antibodies. Nat. Chem. Biol. 2006, 2, 682-688.
38. Bradbury, A. R.; Sidhu, S.; Dubel, S.; McCafferty, J. Beyond natural antibodies: The power of in vitro display technologies. Nat. Biotechnol. 2011, 29, 245-254.
39. Butler, D. C.; McLear, J. A.; Messer, A. Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins. Prog. Neurobiol. 2012, 97, 190-204.
40. Zuber, C.; Mitteregger, G.; Schuhmann, N.; Rey, C.; Knackmuss, S.; Rupprecht, W.; Reusch, U.; Pace, C.; Little, M.; Kretzschmar, H. A.; et al. Delivery of single-chain antibodies (scFvs) directed against the 37/67 kDa laminin receptor into mice via recombinant adeno-associated viral vectors for prion disease gene therapy. J. Gen. Virol. 2008, 89, 2055-2061.
41. Daya, S.; Berns, K. I. Gene therapy using adeno-associated virus vectors. Clin. Microbiol. Rev. 2008, 21, 583-593.
42. Han, T.; Abdel-Motal, U. M.; Chang, D. K.; Sui, J.; Muvaffak, A.; Campbell, J.; Zhu, Q.; Kupper, T. S.; Marasco, W. A. Human anti-CCR4 minibody gene transfer for the treatment of cutaneous t-cell lymphoma. PLoS One 2012, 7, e44455.
43. Hughes, S. H.; Greenhouse, J. J.; Petropoulos, C. J.; Sutrave, P. Adaptor plasmids simplify the insertion of foreign DNA into helper-independent retroviral vectors. J. Virol. 1987, 61, 3004-3012.
44. Atwal, J. K.; Chen, Y.; Chiu, C.; Mortensen, D. L.; Meilandt, W. J.; Liu, Y.; Heise, C. E.; Hoyte, K.; Luk, W.; Lu, Y.; et al. A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo. Sci. Transl. Med. 2011, 3, 84ra43.
45. Hock, C.; Konietzko, U.; Papassotiropoulos, A.; Wollmer, A.; Streffer, J.; von Rotz, R. C.; Davey, G.; Moritz, E.; Nitsch, R. M. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat. Med. 2002, 8, 1270-1275.
46. Boado, R. J.; Zhou, Q. H.; Lu, J. Z.; Hui, E. K.; Pardridge, W. M. Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor. Mol. Pharm. 2010, 7, 237-244.
47. Boado, R. J.; Lu, J. Z.; Hui, E. K.; Pardridge, W. M. IgG-single chain Fv fusion protein therapeutic for Alzheimer's disease: Expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey. Biotechnol. Bioeng. 2010, 105, 627-635.
48. Yu, Y. J.; Zhang, Y.; Kenrick, M.; Hoyte, K.; Luk, W.; Lu, Y.; Atwal, J.; Elliott, J. M.; Prabhu, S.; Watts, R. J. et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci. Transl. Med. 2011, 3, 84ra44.
49. Skrlj, N.; Drevensek, G.; Hudoklin, S.; Romih, R.; Curin Serbec, V.; Dolinar, M. Recombinant single-chain antibody with the Trojan peptide penetratin positioned in the linker region enables cargo transfer across the blood-brain barrier. Appl. Biochem. Biotechnol. 2013, 169, 159-169.
50. Hogrefe, R. I.; Lebedev, A. V.; Zon, G.; Pirollo, K. F.; Rait, A.; Zhou, Q.; Yu, W.; Chang, E. H. Chemically modified short interfering hybrids (siHYBRIDS): Nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2. Nucleos. Nucleot. Nucl. 2006, 25, 889-907.
51. Ferris, R. L.; Jaffee, E. M.; Ferrone, S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: Clinical response, cellular immunity, and immunoescape. J. Clin. Oncol. 2010, 28, 4390-4399.
52. Wan, L.; Zhu, S.; Zhu, J.; Yang, H.; Li, S.; Li, Y.; Cheng, J.; Lu, X. Production and characterization of a CD25-specific scFv-Fc antibody secreted from Pichia pastoris. Appl. Microbiol. Biotechnol. 2012, in press.
53. Yang, K.; Basu, A.; Wang, M.; Chintala, R.; Hsieh, M. C.; Liu, S.; Hua, J.; Zhang, Z.; Zhou, J.; Li, M.; et al. Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. Protein Eng. 2003, 16, 761-770.
54. Tsutsumi, Y.; Onda, M.; Nagata, S.; Lee, B.; Kreitman, R. J.; Pastan, I. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-TAC(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc. Natl. Acad. Sci. USA 2000, 97, 8548-8553.
55. Olkhanud, P. B.; Baatar, D.; Bodogai, M.; Hakim, F.; Gress, R.; Anderson, R. L.; Deng, J.; Xu, M.; Briest, S.; Biragyn, A. Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res. 2009, 69, 5996-6004.
56. Curiel, T. J.; Coukos, G.; Zou, L.; Alvarez, X.; Cheng, P.; Mottram, P.; Evdemon-Hogan, M.; Conejo-Garcia, J. R.; Zhang, L.; Burow, M.; et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10, 942-949.
57. Liu, W.; Onda, M.; Lee, B.; Kreitman, R. J.; Hassan, R.; Xiang, L.; Pastan, I. Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc. Natl. Acad. Sci. USA 2012, 109, 11782-11787.
58. Kreitman, R. J.; Tallman, M. S.; Robak, T.; Coutre, S.; Wilson, W. H.; Stetler-Stevenson, M.; Fitzgerald, D. J.; Lechleider, R.; Pastan, I. Phase i trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J. Clin. Oncol. 2012, 30, 1822-1828.
59. Hassan, R.; Bullock, S.; Premkumar, A.; Kreitman, R. J.; Kindler, H.; Willingham, M. C.; Pastan, I. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus i. V. Infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin. Cancer Res. 2007, 13, 5144-5149.
60. Soliman, H. Immunotherapy strategies in the treatment of breast cancer. Cancer Control 2013, 20, 17-21.
61. Karran, E.; Mercken, M.; De Strooper, B. The amyloid cascade hypothesis for Alzheimer's disease: An appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 2011, 10, 698-712.
62. Grill, J. D.; Cummings, J. L. Current therapeutic targets for the treatment of Alzheimer's disease. Expert Rev. Neurother. 2010, 10, 711-728.
63. Check, E. Nerve inflammation halts trial for Alzheimer's drug. Nature 2002, 415, 462.
64. Orgogozo, J. M.; Gilman, S.; Dartigues, J. F.; Laurent, B.; Puel, M.; Kirby, L. C.; Jouanny, P.; Dubois, B.; Eisner, L.; Flitman, S.; et al. Subacute meningoencephalitis in a subset of patients with AD after abeta42 immunization. Neurology 2003, 61, 46-54.
65. Robert, R.; Wark, K. L. Engineered antibody approaches for Alzheimer's disease immunotherapy. Arch. Biochem. Biophys. 2012, 526, 132-138.
66. Wang, Y. J.; Gao, C. Y.; Yang, M.; Liu, X. H.; Sun, Y.; Pollard, A.; Dong, X. Y.; Wu, X. B.; Zhong, J. H.; Zhou, H. D.; et al. Intramuscular delivery of a single chain antibody gene prevents brain abeta deposition and cognitive impairment in a mouse model of Alzheimer's disease. Brain Behav. Immun. 2010, 24, 1281-1293.
67. Wang, Y. J.; Pollard, A.; Zhong, J. H.; Dong, X. Y.; Wu, X. B.; Zhou, H. D.; Zhou, X. F. Intramuscular delivery of a single chain antibody gene reduces brain abeta burden in a mouse model of Alzheimer's disease. Neurobiol. Aging 2009, 30, 364-376.
68. Fukuchi, K.; Tahara, K.; Kim, H. D.; Maxwell, J. A.; Lewis, T. L.; Accavitti-Loper, M. A.; Kim, H.; Ponnazhagan, S.; Lalonde, R. Anti-abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol. Dis. 2006, 23, 502-511.
69. Ryan, D. A.; Mastrangelo, M. A.; Narrow, W. C.; Sullivan, M. A.; Federoff, H. J.; Bowers, W. J. Abeta-directed single-chain antibody delivery via a serotype-1 AAV vector improves learning behavior and pathology in Alzheimer's disease mice. Mol. Ther. 2010, 18, 1471-1481.
70. Yang, J.; Pattanayak, A.; Song, M.; Kou, J.; Taguchi, H.; Paul, S.; Ponnazhagan, S.; Lalonde, R.; Fukuchi, K. Muscle-directed anti-abeta single-chain antibody delivery via AAV1 reduces cerebral abeta load in an Alzheimer's disease mouse model. J. Mol. Neurosci. 2013, 49, 277-288.
71. Cattepoel, S.; Hanenberg, M.; Kulic, L.; Nitsch, R. M. Chronic intranasal treatment with an antiabeta (30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease. PLoS One 2011, 6, e18296.
72. Crook, Z. R.; Housman, D. Huntington's disease: Can mice lead the way to treatment? Neuron 2011, 69, 423-435.
73. Miller, T. W.; Zhou, C.; Gines, S.; MacDonald, M. E.; Mazarakis, N. D.; Bates, G. P.; Huston, J. S.; Messer, A. A human single-chain v intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease. Neurobiol. Dis. 2005, 19, 47-56.
74. Butler, D. C.; Messer, A. Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments. PLoS One 2011, 6, e29199.
75. Snyder-Keller, A.; McLear, J. A.; Hathorn, T.; Messer, A. Early or late-stage anti-N-terminal huntingtin intrabody gene therapy reduces pathological features in B6. HDR6/1 mice. J. Neuropathol. Exp. Neurol. 2010, 69, 1078-1085.
76. Wang, C. E.; Zhou, H.; McGuire, J. R.; Cerullo, V.; Lee, B.; Li, S. H.; Li, X. J. Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. J. Cell Biol. 2008, 181, 803-816.
77. Zdobnova, T. A.; Stremovskiy, O. A.; Lebedenko, E. N.; Deyev, S. M. Self-assembling complexes of quantum dots and scFv antibodies for cancer cell targeting and imaging. PLoS One 2012, 7, e48248.
78. Xu, W.; Liu, L.; Brown, N. J.; Christian, S.; Hornby, D. Quantum dot-conjugated anti-GRP78 scFv inhibits cancer growth in mice. Molecules 2012, 17, 796-808.
79. Lee, A. S. GRP78 induction in cancer: Therapeutic and prognostic implications. Cancer Res. 2007, 67, 3496-3499.
80. Vigor, K. L.; Kyrtatos, P. G.; Minogue, S.; Al-Jamal, K. T.; Kogelberg, H.; Tolner, B.; Kostarelos, K.; Begent, R. H.; Pankhurst, Q. A.; Lythgoe, M. F.; et al. Nanoparticles functionalized with recombinant single chain Fv antibody fragments (scFv) for the magnetic resonance imaging of cancer cells. Biomaterials 2010, 31, 1307-1315.
81. Olafsen, T.; Wu, A. M. Antibody vectors for imaging. Semin. Nucl. Med. 2010, 40, 167-181.
82. Kumar, P.; Ban, H. S.; Kim, S. S.; Wu, H.; Pearson, T.; Greiner, D. L.; Laouar, A.; Yao, J.; Haridas, V.; Habiro, K.; et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008, 134, 577-586.
83. Pasche, N.; Wulhfard, S.; Pretto, F.; Carugati, E.; Neri, D. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel. Clin. Cancer Res. 2012, 18, 4092-4103.
84. Choi, S.; Lee, J.; Kumar, P.; Lee, K. Y.; Lee, S. K. Single chain variable fragment CD7 antibody conjugated PLGA/HDAC inhibitor immuno-nanoparticles: Developing human T cell-specific nano-technology for delivery of therapeutic drugs targeting latent HIV. J. Control Release 2011, 152 (Suppl 1), e9-e10.